GRIFOLS’ RED-FACED SHAREHOLDERS FINALLY SEE SOME GREENER PASTURES (BUY; 34% UPSIDE)
19/01/23 -" Amidst the volatile markets of the past two years, while Big Pharmas have materially outperformed – thereby regaining their safe-haven status - Smaller Pharmas have been out of favour due to both ..."
Pages
55
Language
English
Published on
19/01/23
You may also be interested by these reports :
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...
21/07/26
The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, ...
20/07/26
Bachem (ADD; Switzerland) is a peptide and oligonucleotide manufacturer, regarded as the most reliable partner in western economies as one of the few ...